Showing 6891-6900 of 8649 results for "".
- Optos Unveils Silverstone Combined Ultra-Widefield Retinal Imaging Device and UWF-Guided Swept Source OCThttps://modernod.com/news/optos-unveils-silverstone-combined-ultra-widefield-retinal-imaging-device-and-uwf-guided-swept-source-oct/2476998/Optos has announced the launch of Silverstone at the American Academy of Ophthalmology in San Francisco. Silverstone is the first-of-its-kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- Johns Hopkins Researchers Advance Search For Safer, Easier Way to Deliver Vision-Saving Gene Therapy to The Retinahttps://modernod.com/news/johns-hopkins-researchers-advance-search-for-safer-easier-way-to-deliver-vision-saving-gene-therapy-to-the-retina/2476942/In experiments with rats, pigs, and monkeys, Johns Hopkins Medicine researchers have developed a way to deliver sight-saving gene therapy to the retina. If proved safe and effective in humans, the technique could provide a new, more permanent therapeutic option for patients
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- Santen Expands Into Surgical Devices and Publishes Real-World Evidence in Dry Eye Diseasehttps://modernod.com/news/santen-expands-into-surgical-devices-and-publishes-real-world-evidence-in-dry-eye-disease/2476923/In addition to launching a new monofocal, hydrophobic IOL, xact Mono-EDoF, a panel of experts including Ike K. Ahmed, reviewed current surgical techniques and introduced Santen’s Preserflo MicroShunt device at the recent ESCRS meeting in Paris. Preserflo MicroShunt is a surgical dev
- Tangible Science and VSP Optics Co-develop New Daily Disposable Silicone Hydrogel Contact Lenshttps://modernod.com/news/tangible-science-and-vsp-optics-co-develop-new-daily-disposable-silicone-hydrogel-contact-lens/2476916/Tangible Science announced the launch of Unity BioSync contact lenses, which the company is describing as the first daily disposable silicone hydrogel contact lens featuring a modified formula of the patented Tangible Hydra-PEG polymer technology that is bonded to the surface of the lens. Co-deve
- Zeiss and IDOC Partner to Bring Medical and Vision Care Products to Independent Optometrists Nationwidehttps://modernod.com/news/zeiss-and-idoc-partner-to-bring-medical-and-vision-care-products-to-independent-optometrists-nationwide/2476890/IDOC, Zeiss Vision Care US and Zeiss Medical Technology announced a 5-year agreement to bring Zeiss’ lab services, lens products and medical equipment to all 3,000+ IDOC independent optometrists across the United Stat
- Cassini to Reveal New Cassini Device at ESCRShttps://modernod.com/news/cassini-to-reveal-new-cassini-device-at-the-escrs-in-paris/2476880/Cassini announced that it will reveal its new Cassini device at the 37th Congress of European Society of Cataract and Refractive Surgeons in Paris. This product introduction marks the next chapter of product design, with latest camera technology, improved patient comfort and great usability.
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-completes-enrolment-of-phase-1-clinical-trial-evaluating-thr-687-for-the-treatment-of-dme/2476849/Oxurion NV announced the completion of enrollment of patients in a phase 1 trial with THR-687. The open-label, multicenter, dose escalation phase 1 study is evaluating the safety of a single intravitreal injection of escalating dose levels (3) of THR-687 for the treatment of patients with diabeti